Pipeline Data Lift JNJ, LLY, PFE; Abbott Extends Dividend

Johnson & Johnson ($JNJ) reported breakthrough Phase 2/3 ENERGY trial results for IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia, a rare anemia with no current FDA-approved therapies. The drug significantly improved hemoglobin levels and fatigue in trial patients, with a safety profile consistent with prior use. The data supported a supplemental Biologics License Application, which has received U.S. FDA Priority Review, and IMAAVY is being studied across multiple autoimmune indications. $JNJ shares have gained 53% over the past year and 15% year-to-date.

Pfizer ($PFE) released detailed Phase 2b results for berobenatide, its investigational monthly GLP-1 receptor agonist for obesity, showing proof of concept with favorable tolerability and low reported adverse events. $PFE has started Phase 3 trials and outlined a broader clinical program for berobenatide as part of its late-stage obesity pipeline. Eli Lilly ($LLY) reported Phase 1 data for AJ1-11095, a first-in-class type II JAK2 inhibitor, in myelofibrosis patients whose disease continued after prior type I JAK2 inhibitor treatment. Early results showed encouraging safety findings and clinical activity in this difficult-to-treat group, highlighting a broader pipeline beyond the company's widely recognized obesity drug portfolio.

Abbott Laboratories ($ABT) secured CE Mark for its Libre Duo dual glucose-ketone sensors and expanded a commercialization agreement with MiniMed, targeting diabetic ketoacidosis risks. The company's board declared a quarterly dividend of $0.63 per share, payable on August 17, 2026, to shareholders of record on July 15, marking the company's 410th consecutive quarterly payout since 1924. The dual-sensor technology underscores how Abbott's diabetes technology is addressing clinical complications highlighted by recent company-backed research.

UnitedHealth Group ($UNH) was highlighted during Mad Money as part of rotation into defensive sectors, with the host calling the company's CEO "legendary" and noting the stock as a managed care play. The stock pulled back during the afternoon session. Humana was also mentioned in the same defensive rotation context, though no specific data points were provided.

Harbour BioMed secured a complete victory in a patent infringement lawsuit against Amgen ($AMGN) and its subsidiary Teneobio in the United States District Court for the District of Delaware. A jury returned a decisive verdict in Harbour BioMed's favor, representing a landmark development in the global antibody patent landscape. The outcome could reshape competitive dynamics in antibody therapeutics across immunology and oncology.

Bio Usawa, a biotechnology company dedicated to expanding access to high-quality biologic medicines across Africa, announced the appointment of Dr. Aida Habtezion, former Chief Medical Officer at Pfizer ($PFE), to its Board of Directors. The appointment marks a milestone as the company accelerates efforts to build sustainable biotechnology manufacturing capacity on the continent and improve access to life-changing therapies for patients across Africa. Dr. Habtezion's experience is expected to support the company's operational and strategic expansion.

Investors are monitoring $PFE Phase 3 trial progress for berobenatide and broader commercialization timelines for obesity assets, while $JNJ IMAAVY Priority Review decision timing remains a near-term regulatory catalyst. $ABT commercialization of the Libre Duo dual-sensor platform in European markets could serve as a proof point for diabetes technology adoption. Moderna ($MRNA) CEO discussion on pandemic preparedness and bioterrorism underscores ongoing focus on vaccine platform expansion beyond COVID-19 and into oncology.